U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973863) titled 'A Phase 1a/1b Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors' on May 07.
Brief Summary: This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion.
The study will be conducted in three parts, with Part 1 currently open for enrollment.
The primary objectives of the study are to:
* Evaluate the safety and tolerability of PEP08, PK and PD
* Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)
* Assess prelimi...